← Leaderboards
Douglas H Thamm
Mbc Pharma, Inc.
$297,101
Attributed
$594,202
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $300K · FY2017–18$500K$375K$250K$125K$0
'17
'18
Funding mix
By agency
NIH$594,202 · 1
By mechanism
R43$594,202 · 1
Top collaborators
- Shawn Patrick Zinnen2 shared
Others in their field
Other Emerging Leaders on “Aerobic”
- Susan M Landau · University Of California Berkeley$47,252,026
- Jessica Scott · Sloan-Kettering Inst Can Research$10,593,887
- Alexander Egbe · Mayo Clinic Rochester$7,415,297
- Andrei G. Vlassenko · Washington University$6,750,146
- Pierce Boyne · University Of Cincinnati$5,412,610
- Mark Andrew Sarzynski · Beth Israel Deaconess Medical Center$4,936,886
Research focus
AerobicAffinityAggressive TherapyAmputationAnaerobic BacteriaAntibioticsAntibiotic TherapyAnti-Infective AgentsAntineoplastic AgentsAutomobile DrivingBacterial ModelBaseBindingBisphosphonateBlood CirculationBlood VesselsBoneBone DiseasesBone ResorptionBone TurnoverCancer PatientChronicCiprofloxacinAdverse Event